Q1 Earnings Forecast for Rezolute Issued By HC Wainwright

Rezolute, Inc. (NASDAQ:RZLT) – HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Rezolute in a research note issued to investors on Thursday, February 13th. HC Wainwright analyst D. Tsao expects that the company will earn ($0.33) per share for the quarter. HC Wainwright has a “Buy” rating and a $14.00 price objective on the stock. The consensus estimate for Rezolute’s current full-year earnings is ($0.99) per share. HC Wainwright also issued estimates for Rezolute’s Q2 2026 earnings at ($0.32) EPS, Q3 2026 earnings at ($0.38) EPS and Q4 2026 earnings at ($0.40) EPS.

RZLT has been the topic of a number of other reports. Wedbush reaffirmed an “outperform” rating and issued a $112.00 target price on shares of Rezolute in a report on Monday, November 4th. JMP Securities raised their price objective on Rezolute from $8.00 to $9.00 and gave the stock a “market outperform” rating in a research note on Thursday, February 13th. Craig Hallum upgraded Rezolute to a “strong-buy” rating in a research note on Tuesday, February 4th. Finally, Guggenheim restated a “buy” rating on shares of Rezolute in a research note on Monday, February 10th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Rezolute has a consensus rating of “Buy” and an average price target of $24.38.

Rezolute Price Performance

Shares of Rezolute stock opened at $4.77 on Monday. Rezolute has a 1-year low of $1.41 and a 1-year high of $6.19. The company’s fifty day simple moving average is $4.85 and its 200-day simple moving average is $4.90. The stock has a market capitalization of $276.37 million, a PE ratio of -3.76 and a beta of 1.10.

Rezolute (NASDAQ:RZLT) last posted its quarterly earnings data on Wednesday, February 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.11.

Institutional Trading of Rezolute

Several hedge funds have recently bought and sold shares of RZLT. Alpine Global Management LLC purchased a new position in shares of Rezolute during the fourth quarter valued at about $54,000. Woodline Partners LP grew its holdings in Rezolute by 2,817.1% during the 4th quarter. Woodline Partners LP now owns 1,089,345 shares of the company’s stock valued at $5,338,000 after buying an additional 1,052,002 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. increased its stake in Rezolute by 48.5% in the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 19,799 shares of the company’s stock worth $97,000 after acquiring an additional 6,470 shares during the last quarter. Point72 Europe London LLP purchased a new stake in shares of Rezolute during the 4th quarter worth approximately $720,000. Finally, Man Group plc purchased a new stake in shares of Rezolute during the 4th quarter worth approximately $425,000. Hedge funds and other institutional investors own 82.97% of the company’s stock.

Insider Buying and Selling

In related news, CFO Daron Evans bought 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 18th. The stock was bought at an average cost of $4.29 per share, with a total value of $42,900.00. Following the completion of the purchase, the chief financial officer now owns 150,900 shares of the company’s stock, valued at approximately $647,361. The trade was a 7.10 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. 18.39% of the stock is owned by insiders.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.